Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase Inhibition Results in Biphasic Alteration of Epidermal Homeostasis with Keratinocytic Apoptosis and Pigmentation Disorders

被引:50
作者
Schad, Karin [1 ]
Conzett, Katrin Baumann [1 ]
Zipser, Marie C. [1 ]
Enderlin, Valerie [1 ]
Kamarashev, Jivko [1 ]
French, Lars E. [1 ]
Dummer, Reinhard [1 ]
机构
[1] Univ Zurich Hosp, Dept Dermatol, CH-8091 Zurich, Switzerland
关键词
GROWTH-FACTOR RECEPTOR; CANCER-PATIENTS; MECHANISMS; CETUXIMAB; MELANOMA; EXPRESS;
D O I
10.1158/1078-0432.CCR-09-1766
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Raf/mitogen-activated protein/extracellular signal-regulated kinase (ERK) kinase (MEK)/ERK signaling pathway is constitutively activated in melanoma. AZD6244 blocks MEK1/2, inhibiting ERK phosphorylation. We focus on associated cutaneous toxicity and we attempt to understand the underlying pathophysiology and design treatment strategies. Experimental Design: Dermatologic conditions of 22 patients with unresectable melanoma stage III/IV in a phase II trial were evaluated. Thirteen patients received AZD6244 initially, and nine patients were treated with AZD6244 following tumor progression with temozolomide. Biopsies were compared with matched controls in normal skin. Immunohistochemistry was performed. Half-side treatment of acute skin toxicity compared therapeutic options. Results: Nineteen of 22 (86%) AZD6244-treated patients presented with cutaneous eruptions. Seventeen patients (77%) developed acute papulopustular rash. Chronic skin changes included xerosis, paronychia, and fissured fingertips, resembling cutaneous toxicity of epidermal growth factor receptor inhibition. In addition, we observed reduced pigmentation of hair and skin. Histology of acute skin lesions revealed a significant increase of apoptotic keratinocytes (P = 0.0008), focal neutrophilic infiltrates, destruction of the adnexal structures by neutrophils, and reduced cytokeratins. A significant proliferation shift from basal to suprabasal keratinocytes was shown in acute and chronic lesions. The number and viability of melanocytes was not affected. Corticosteroids plus antibacterial topical therapy ameliorate acute skin toxicity. Conclusions: AZD6244-associated skin reactions partly overlap with those observed upon epidermal growth factor receptor inhibition. Additionally, pigmentation of skin and hair is affected. The interruption of the MEK signaling pathway results in an acute keratinocyte stress response with disturbed epidermal homeostasis, inflammation, and tissue damage. Chronic adaptation controls inflammatory tissue damage but leads to cutaneous malfunctions that explain chronic skin toxicity. Clin Cancer Res; 16(3); 1058-64. (C) 2010 AACR.
引用
收藏
页码:1058 / 1064
页数:7
相关论文
共 28 条
  • [21] Cutaneous side-effects of kinase inhibitors and blocking antibodies
    Robert, C
    Soria, JC
    Spatz, A
    Le Cesne, A
    Malka, D
    Pautier, P
    Wechsler, J
    Lhomme, C
    Escudier, B
    Boige, V
    Armand, JP
    Le Chevalier, T
    [J]. LANCET ONCOLOGY, 2005, 6 (07) : 491 - 500
  • [22] Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor
    Saltz, LB
    Meropol, NJ
    Loehrer, PJ
    Needle, MN
    Kopit, J
    Mayer, RJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (07) : 1201 - 1208
  • [23] SCHAD K, 2008, ASCO ANN M P POSTM E, P26
  • [24] Targeting intracellular signaling pathways as a novel strategy in melanoma therapeutics
    Smalley, KSM
    Herlyn, M
    [J]. TUMOR PROGRESSION AND THERAPEUTIC RESISTANCE, 2005, 1059 : 16 - 25
  • [25] High-throughput oncogene mutation profiling in human cancer
    Thomas, Roman K.
    Baker, Alissa C.
    DeBiasi, Ralph M.
    Winckler, Wendy
    LaFramboise, Thomas
    Lin, William M.
    Wang, Meng
    Feng, Whei
    Zander, Thomas
    MacConnaill, Laura E.
    Lee, Jeffrey C.
    Nicoletti, Rick
    Hatton, Charlie
    Goyette, Mary
    Girard, Luc
    Majmudar, Kuntal
    Ziaugra, Liuda
    Wong, Kwok-Kin
    Gabriel, Stacey
    Beroukhim, Rameen
    Peyton, Michael
    Barretina, Jordi
    Dutt, Amit
    Emery, Caroline
    Greulich, Heidi
    Shah, Kinjal
    Sasaki, Hidefumi
    Gazdar, Adi
    Minna, John
    Armstrong, Scott A.
    Mellinghoff, Ingo K.
    Hodi, F. Stephen
    Dranoff, Glenn
    Mischel, Paul S.
    Cloughesy, Tim F.
    Nelson, Stan F.
    Liau, Linda M.
    Mertz, Kirsten
    Rubin, Mark A.
    Moch, Holger
    Loda, Massimo
    Catalona, William
    Fletcher, Jonathan
    Signoretti, Sabina
    Kaye, Frederic
    Anderson, Kenneth C.
    Demetri, George D.
    Dummer, Reinhard
    Wagner, Stephan
    Herlyn, Meenhard
    [J]. NATURE GENETICS, 2007, 39 (03) : 347 - 351
  • [26] CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment
    Trotti, A
    Colevas, AD
    Setser, A
    Rusch, V
    Jaques, D
    Budach, V
    Langer, C
    Murphy, B
    Cumberlin, R
    Coleman, CN
    Rubin, P
    [J]. SEMINARS IN RADIATION ONCOLOGY, 2003, 13 (03) : 176 - 181
  • [27] Primary cutaneous CD8+ and CD56+ T-cell lymphomas express HLA-G and killer-cell inhibitory ligand, ILT2
    Urosevic, M
    Kamarashev, J
    Burg, G
    Dummer, R
    [J]. BLOOD, 2004, 103 (05) : 1796 - 1798
  • [28] Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor
    Vanhoefer, U
    Tewes, M
    Rojo, F
    Dirsch, O
    Schleucher, N
    Rosen, O
    Tillner, J
    Kovar, A
    Braun, AH
    Trarbach, T
    Seeber, S
    Harstrick, A
    Baselga, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (01) : 175 - 184